585 related articles for article (PubMed ID: 26662572)
1. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
Tice JA; Kazi DS; Pearson SD
JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
[No Abstract] [Full Text] [Related]
2. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
Henry CA; Lyon RA; Ling H
Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
Christiansen MK; Jensen HK
Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
[TBL] [Abstract][Full Text] [Related]
5. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
Avci A; Demir K; Altunkeser BB
Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
[TBL] [Abstract][Full Text] [Related]
6. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
Everett BM; Smith RJ; Hiatt WR
N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323
[No Abstract] [Full Text] [Related]
7. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Ling H; Burns TL; Hilleman DE
Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
Paton DM
Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
[TBL] [Abstract][Full Text] [Related]
10. [PCSK9 inhibitors: new treatment to lower cholesterol].
Gencer B; Rodondi N; Mach F
Rev Med Suisse; 2016 Mar; 12(508):440-2, 444. PubMed ID: 27089600
[TBL] [Abstract][Full Text] [Related]
11. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
13. PCSK9 antibodies: A new class of lipid-lowering drugs.
Gouni-Berthold I
Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
[TBL] [Abstract][Full Text] [Related]
14. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
Shen L; Peng H; Xu D; Zhao S
Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
[TBL] [Abstract][Full Text] [Related]
15. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
[TBL] [Abstract][Full Text] [Related]
16. Alirocumab (Praluent) to lower LDL-Cholesterol.
Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881
[No Abstract] [Full Text] [Related]
17. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
[TBL] [Abstract][Full Text] [Related]
18. Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia.
Devito F; Zito A; Ricci G; Carbonara R; Dentamaro I; Cortese F; Carbonara S; Ciccone MM
Pharmacol Res; 2015 Dec; 102():168-75. PubMed ID: 26455563
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
Yang E
Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
